Study protocol: A randomized, doubleblind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations

被引：3

作者：

Cowan J. ^{[1
,2
]}

Mulpuru S. ^{[1
,2
]}

Aaron S. ^{[1
,2
]}

Alvarez G. ^{[1
,2
]}

Giulivi A. ^{[2
,3
]}

Corrales-Medina V. ^{[2
]}

Thiruganasambandamoorthy V. ^{[2
,4
]}

Thavorn K. ^{[2
,5
,6
]}

Mallick R. ^{[2
]}

Cameron D.W. ^{[1
,2
]}

机构：

[1] Department of Medicine, Division of Infectious Diseases, University of Ottawa, 501 Smyth Road, Ottawa, K1H 8L6, ON

[2] Ottawa Hospital Research Institute, Ottawa, ON

[3] Department of Pathology and Laboratory Medicine, Ottawa Hospital, University of Ottawa, Ottawa, ON

[4] Department of Emergency Medicine, Ottawa Hospital, University of Ottawa, Ottawa, ON

[5] School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON

[6] Institute of Clinical and Evaluative Sciences, Toronto, ON

来源：

Pilot and Feasibility Studies | / 4卷 / 1期

关键词：

COPD; COPD exacerbation; Feasibility and safety; Immunoglobulin; Pilot study; Randomized clinical trial;

D O I：

10.1186/s40814-018-0327-z

中图分类号：

学科分类号：

摘要：

Background: Chronic obstructive pulmonary disease (COPD) is a chronic progressive inflammatory disease of the airways, associated with frailty, disability, co-morbidity, and mortality. Individuals with COPD experience increased risk and rates of acute exacerbation as their lung disease worsens. Current treatments to prevent acute exacerbation of COPD (AECOPD) are only modestly effective. New therapies are needed to improve the quality of life and clinical outcomes for individuals living with COPD and especially for those prone to frequent recurrent AECOPD. Recent research has suggested an association of gammaglobulin or immunoglobulin G levels with AECOPD and a favorable effect of an immunoglobulin treatment on the frequency of recurrent AECOPD, healthcare provider visits, treatments, and hospitalizations. However, control trials are required to confirm this apparent association and therapeutic effect. This study aims to assess if intravenous immunoglobulin (IVIG) therapy is feasible, safe, tolerable, and potentially effective in reducing the frequency of recurrent AECOPD. Methods/design: Adult COPD patients at The Ottawa Hospital (TOH) will be recruited to partake in a randomized double-blind, parallel, two-arm, placebo control trial. Eligible patients will be administered either IVIG or normal saline following 1:1 randomization and every 4 weeks for 1 year. The primary outcome of feasibility will be determined by recruitment, patient adherence, safety and tolerance, success of the follow-up procedures, and outcome measurement. The safety and tolerability will be assessed through adverse events, adherence, and study withdrawals. Efficacy trends will be investigated by assessing incidence rates of AECOPD, improvement in quality of life, and healthcare services use and cost. Discussion: The study results will inform larger studies designed to confirm a clinically significant therapeutic effect in identifiable populations which would be a major advance in the care of COPD patients. Trial registration number: ClinicalTrial.gov, NCT03018652 and NCT02690038. © The Author(s). 2018.

引用

共 25 条

[1] Benedy S., The human and economic burden of COPD: A leading cause of hospital admission in Canada, Ottawa: Canadian Thoracic Society, (2010)
[2] Niewoehner D.E., Rice K., Cote C., Paulson D., Cooper J.A.D., Korducki L., Et al., Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: A randomized trial, Ann Intern Med, 143, 5, pp. 317-326, (2005)
[3] Hurst J.R., Vestbo J., Anzueto A., Locantore N., Mullerova H., Tal-Singer R., Et al., Susceptibility to exacerbation in chronic obstructive pulmonary disease, N Engl J Med, 363, 12, pp. 1128-1138, (2010)
[4] Seemungal T.A., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., Wedzicha J.A., Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 157, 5, pp. 1418-1422, (1998)
[5] Toy E.L., Gallagher K.F., Stanley E.L., Swensen A.R., Duh M.S., The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: A review, COPD. Analysis Group, Inc, Lakewood, 7, 3, pp. 214-228, (2010)
[6] Mullerova H., Maselli D.J., Locantore N., Vestbo J., Hurst J.R., Wedzicha J.A., Et al., Hospitalized exacerbations of COPD: Risk factors and outcomes in the ECLIPSE cohort, Chest United States, 147, 4, pp. 999-1007, (2015)
[7] Baker C.L., Zou K.H., Su J., Risk assessment of readmissions following an initial COPD-related hospitalization, Int J Chron Obstruct Pulmon Dis, 8, pp. 551-559, (2013)
[8] (2017)
[9] Albert R.K., Connett J., Bailey W.C., Casaburi R., Cooper J.A., Criner G.J., Et al., Azithromycin for prevention of exacerbations of COPD, N Engl J Med, 365, 8, pp. 689-698, (2011)
[10] Zheng J.P., Wen F.Q., Bai C.X., Wan H.Y., Kang J., Chen P., Et al., Twice daily Nacetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): A randomised, double-blind placebo-controlled trial, Lancet Respir Med, 2, 3, pp. 187-194, (2014)

← 1 2 3 →